Bayer’s Eylea Sees Good Start In Japan Thanks To Partnering

Bayer's three new products – Eylea, Xarelto and Stivarga – are off to a good start in the marketplace, says interim pharma head Wolfgang Plischke. Eylea has 48% Japanese market share for wet AMD.

More from Japan

More from Focus On Asia